CerFlux, Inc.
CerFlux is a Birmingham-based cancer biotech company dedicated to creating advanced, personalized medicine solutions. Their innovative technologies include the patented ChipMux® biopsy-on-a-chip for testing multiple anticancer agents directly on tumor biopsy tissue, aiming to improve cancer treatment outcomes through rapid, personalized, and effective therapies. The company actively participates in industry events, receives grants and awards, and collaborates with research institutions to advance cancer research and personalized medicine.
Industries
Nr. of Employees
small (1-50)
Products
Microchamber array multiplexer device for biopsy testing
Chip-based microchamber array device designed to expose a single intact tumor biopsy to multiple fluids/therapeutic agents concurrently while preserving tissue microarchitecture and enabling multiplexed efficacy assessment.
Microchamber array multiplexer device for biopsy testing
Chip-based microchamber array device designed to expose a single intact tumor biopsy to multiple fluids/therapeutic agents concurrently while preserving tissue microarchitecture and enabling multiplexed efficacy assessment.
Services
Rapid ex vivo therapeutic efficacy testing for patients
Laboratory service that screens multiple approved or experimental therapeutic regimens concurrently on a patient’s biopsy tissue to identify likely effective and ineffective options prior to clinical treatment.
Preclinical efficacy screening for pharmaceutical and biotech R&D
Research service to evaluate panels of preclinical candidate molecules or formulations on patient-derived tumor tissue or organoid surrogates to estimate clinical relevance and prioritize assets for development.
AI/ML integration and translational analytics consulting
Advisory and data-analytics services to integrate ex vivo assay outputs with machine learning models to produce individualized efficacy scores and support translational decision-making and trial design.
Device prototyping and rapid fabrication services
In-house prototyping and small-batch fabrication services including microfabrication and 3D printing for device development, auxiliary products, and rapid-response production of PPE or device adaptors.
Rapid ex vivo therapeutic efficacy testing for patients
Laboratory service that screens multiple approved or experimental therapeutic regimens concurrently on a patient’s biopsy tissue to identify likely effective and ineffective options prior to clinical treatment.
Preclinical efficacy screening for pharmaceutical and biotech R&D
Research service to evaluate panels of preclinical candidate molecules or formulations on patient-derived tumor tissue or organoid surrogates to estimate clinical relevance and prioritize assets for development.
AI/ML integration and translational analytics consulting
Advisory and data-analytics services to integrate ex vivo assay outputs with machine learning models to produce individualized efficacy scores and support translational decision-making and trial design.
Device prototyping and rapid fabrication services
In-house prototyping and small-batch fabrication services including microfabrication and 3D printing for device development, auxiliary products, and rapid-response production of PPE or device adaptors.
Expertise Areas
- Personalized oncology diagnostics
- Ex vivo tumor modeling and multiplexed testing
- Microfluidics and microchamber array development
- Translational research partnerships and analytics
Key Technologies
- Microfluidic microchamber arrays
- Ex vivo core-biopsy testing workflows
- High-content fluorescence imaging
- Custom image-processing algorithms